Biophytis S.A. (ALBPS.PA)
EUR 0.33
(0.92%)
EUR 0.33
(0.92%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.7 Million EUR | 151.91% |
| 2022 | 1.07 Million EUR | 112.55% |
| 2021 | -8.55 Million EUR | -363.24% |
| 2020 | 3.24 Million EUR | -63.54% |
| 2019 | 8.9 Million EUR | 243.52% |
| 2018 | -6.2 Million EUR | 67.06% |
| 2017 | -18.84 Million EUR | -853.16% |
| 2016 | -1.97 Million EUR | 77.03% |
| 2015 | -8.6 Million EUR | -1303.19% |
| 2014 | 715.31 Thousand EUR | 70.22% |
| 2013 | 420.22 Thousand EUR | 1079.32% |
| 2012 | -42.91 Thousand EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 7.35 Million EUR | 2.22% |
| 2024 Q1 | 7.35 Million EUR | 172.22% |
| 2023 FY | 2.7 Million EUR | 151.91% |
| 2023 Q1 | 6.87 Million EUR | 540.63% |
| 2023 Q2 | 3.8 Million EUR | -44.7% |
| 2023 Q4 | 2.7 Million EUR | 2.04% |
| 2023 Q3 | 2.64 Million EUR | -30.31% |
| 2022 Q2 | -5.33 Million EUR | -388.37% |
| 2022 Q4 | 1.07 Million EUR | -66.95% |
| 2022 FY | 1.07 Million EUR | 112.55% |
| 2022 Q3 | 3.24 Million EUR | 160.89% |
| 2022 Q1 | -1.09 Million EUR | 87.23% |
| 2021 Q3 | -6.59 Million EUR | 21.55% |
| 2021 FY | -8.55 Million EUR | -363.24% |
| 2021 Q1 | -4.82 Million EUR | -248.46% |
| 2021 Q2 | -8.4 Million EUR | -74.26% |
| 2021 Q4 | -8.55 Million EUR | -29.7% |
| 2020 Q3 | 9.2 Million EUR | 1211.71% |
| 2020 Q1 | -828 Thousand EUR | -110.85% |
| 2020 Q2 | -828 Thousand EUR | 0.0% |
| 2020 Q4 | 3.24 Million EUR | -64.71% |
| 2020 FY | 3.24 Million EUR | -63.54% |
| 2019 FY | 8.9 Million EUR | 243.52% |
| 2019 Q3 | 10.11 Million EUR | 98.86% |
| 2019 Q1 | -599 Thousand EUR | 90.42% |
| 2019 Q4 | 7.62 Million EUR | -24.61% |
| 2019 Q2 | 5.08 Million EUR | 949.42% |
| 2018 Q4 | -6.25 Million EUR | 0.0% |
| 2018 FY | -6.2 Million EUR | 67.06% |
| 2018 Q3 | -6.25 Million EUR | 50.9% |
| 2018 Q2 | -12.73 Million EUR | -164.13% |
| 2018 Q1 | 19.85 Million EUR | 205.38% |
| 2017 Q4 | -18.84 Million EUR | 0.25% |
| 2017 FY | -18.84 Million EUR | -853.16% |
| 2017 Q1 | -3.36 Million EUR | -70.16% |
| 2017 Q2 | -3.31 Million EUR | 1.37% |
| 2017 Q3 | -18.89 Million EUR | -469.35% |
| 2016 Q1 | -6.35 Million EUR | 26.18% |
| 2016 Q4 | -1.97 Million EUR | 2.18% |
| 2016 FY | -1.97 Million EUR | 77.03% |
| 2016 Q3 | -2.02 Million EUR | 67.97% |
| 2016 Q2 | -6.31 Million EUR | 0.68% |
| 2015 Q3 | -8.65 Million EUR | -1013.53% |
| 2015 Q1 | 946.87 Thousand EUR | 32.37% |
| 2015 FY | -8.6 Million EUR | -1303.19% |
| 2015 Q4 | -8.6 Million EUR | 0.5% |
| 2015 Q2 | 946.87 Thousand EUR | 0.0% |
| 2014 Q3 | 715.31 Thousand EUR | 0.0% |
| 2014 Q1 | 43 Thousand EUR | 0.0% |
| 2014 Q4 | 715.31 Thousand EUR | 0.0% |
| 2014 FY | 715.31 Thousand EUR | 70.22% |
| 2013 FY | 420.22 Thousand EUR | 1079.32% |
| 2012 FY | -42.91 Thousand EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | 478.571% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 101.376% |
| Adocia SA | 127 Thousand EUR | -2028.346% |
| Aelis Farma SA | -16.19 Million EUR | 116.693% |
| Advicenne S.A. | 12.17 Million EUR | 77.799% |
| genOway Société anonyme | 2.97 Million EUR | 9.081% |
| IntegraGen SA | -709.74 Thousand EUR | 480.839% |
| Medesis Pharma S.A. | 1.15 Million EUR | -133.377% |
| Neovacs S.A. | -237.08 Thousand EUR | 1240.088% |
| NFL Biosciences SA | -2.27 Million EUR | 218.768% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 37.955% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | 425.448% |
| Sensorion SA | 1.37 Million EUR | -96.122% |
| Theranexus Société Anonyme | 2.44 Million EUR | -10.59% |
| TME Pharma N.V. | -1.07 Million EUR | 350.51% |
| Valbiotis SA | -18.13 Million EUR | 114.902% |
| TheraVet SA | 12.78 Thousand EUR | -21041.963% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | -23.991% |
| argenx SE | -1.83 Billion EUR | 100.147% |
| BioSenic S.A. | 28.04 Million EUR | 90.362% |
| Celyad Oncology SA | -6.1 Million EUR | 144.297% |
| DBV Technologies S.A. | -114.95 Million USD | 102.351% |
| Galapagos NV | -157.2 Million EUR | 101.719% |
| Genfit S.A. | -7.61 Million EUR | 135.514% |
| GeNeuro SA | 5.91 Million EUR | 54.267% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 110.764% |
| Innate Pharma S.A. | -30.71 Million EUR | 108.801% |
| Inventiva S.A. | 10.48 Million EUR | 74.23% |
| MaaT Pharma SA | -10.2 Million EUR | 126.487% |
| MedinCell S.A. | 39.5 Million EUR | 93.157% |
| Nanobiotix S.A. | -24.71 Million EUR | 110.935% |
| Onward Medical N.V. | -12.89 Million EUR | 120.963% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -88.977% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 90.036% |
| Oxurion NV | 10.71 Million EUR | 74.762% |
| Pharming Group N.V. | 99.4 Million EUR | 97.281% |
| Poxel S.A. | 44.55 Million EUR | 93.934% |
| GenSight Biologics S.A. | 16.29 Million EUR | 83.411% |
| Transgene SA | -14.4 Million EUR | 118.759% |
| Financière de Tubize SA | 78.62 Million EUR | 96.562% |
| UCB SA | 2.17 Billion EUR | 99.876% |
| Valneva SE | 82.73 Million EUR | 96.733% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 114.592% |